WT1 and ovarian cancer: Subgroup analyses by cancer type showed that WT1 positive expression had an unfavorable impact on DFS/RFS/PFS for patients with carcinoma (metaHR = 2.14, 95%CI = 1.37–3.36), including ovarian cancer (metaHR = 2.61, 95% CI = 1.94–3.52).